GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
551
Cartesian Therapeutics
RNAC
$277M
| $9.56K | ﹤0.01% |
+534
| New | +$9.56K |
|
552
UroGen Pharma
URGN
$873M
| $9.44K | ﹤0.01% |
+886
| New | +$9.44K |
|
553
HUTCHMED
HCM
$2.74B
| $9.38K | ﹤0.01% |
+651
| New | +$9.38K |
|
554
Allogene Therapeutics
ALLO
$255M
| $9.38K | ﹤0.01% |
+4,403
| New | +$9.38K |
|
555
Zevra Therapeutics
ZVRA
$502M
| $9.35K | ﹤0.01% |
+1,121
| New | +$9.35K |
|
556
Alpha Teknova
TKNO
$233M
| $9.34K | ﹤0.01% |
+1,119
| New | +$9.34K |
|
|
BFS
557
Saul Centers
BFS
$812M
| $9.27K | ﹤0.01% |
+239
| New | +$9.27K |
|
558
MaxCyte
MXCT
$150M
| $9.21K | ﹤0.01% |
+2,215
| New | +$9.21K |
|
559
Esperion Therapeutics
ESPR
$540M
| $9.1K | ﹤0.01% |
+4,137
| New | +$9.1K |
|
560
SIGA Technologies
SIGA
$603M
| $9.01K | ﹤0.01% |
+1,499
| New | +$9.01K |
|
561
OmniAb
OABI
$246M
| $9K | ﹤0.01% |
+2,541
| New | +$9K |
|
562
Phibro Animal Health
PAHC
$1.6B
| $8.97K | ﹤0.01% |
+427
| New | +$8.97K |
|
563
Monte Rosa Therapeutics
GLUE
$305M
| $8.95K | ﹤0.01% |
+1,290
| New | +$8.95K |
|
|
UHT
564
Universal Health Realty Income Trust
UHT
$574M
| $8.82K | ﹤0.01% |
+237
| New | +$8.82K |
|
|
GMRE
565
Global Medical REIT
GMRE
$508M
| $8.68K | ﹤0.01% |
+1,124
| New | +$8.68K |
|
566
KalVista Pharmaceuticals
KALV
$796M
| $8.67K | ﹤0.01% |
+1,023
| New | +$8.67K |
|
567
Aura Biosciences
AURA
$403M
| $8.62K | ﹤0.01% |
+1,049
| New | +$8.62K |
|
568
Personalis
PSNL
$465M
| $8.57K | ﹤0.01% |
+1,483
| New | +$8.57K |
|
569
AnaptysBio
ANAB
$613M
| $8.46K | ﹤0.01% |
+639
| New | +$8.46K |
|
|
OLP
570
One Liberty Properties
OLP
$511M
| $8.39K | ﹤0.01% |
+308
| New | +$8.39K |
|
|
ALX
571
Alexander's
ALX
$1.2B
| $8.2K | ﹤0.01% |
+41
| New | +$8.2K |
|
572
Codexis
CDXS
$218M
| $8.15K | ﹤0.01% |
+1,709
| New | +$8.15K |
|
573
Galapagos
GLPG
$2.2B
| $8.06K | ﹤0.01% |
+293
| New | +$8.06K |
|
574
Regenxbio
RGNX
$490M
| $8.04K | ﹤0.01% |
+1,040
| New | +$8.04K |
|
|
CLDT
575
Chatham Lodging
CLDT
$363M
| $7.89K | ﹤0.01% |
+882
| New | +$7.89K |
|